Merck & Company Inc (MRK)vsArcus Biosciences Inc (RCUS)
MRK
Merck & Company Inc
$120.79
-2.77%
HEALTHCARE · Cap: $285.64B
RCUS
Arcus Biosciences Inc
$23.19
-6.08%
HEALTHCARE · Cap: $2.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 27768% more annual revenue ($65.77B vs $236.00M). MRK leads profitability with a 13.6% profit margin vs -156.4%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
RCUS
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Margin of Safety
+87.3%
Fair Value
$168.11
Current Price
$23.19
$144.92 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Weak financial health signals
ROE of -70.4% — below average capital efficiency
Revenue declined 39.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : RCUS
The strongest argument for RCUS centers on Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : RCUS
The primary concerns for RCUS are EPS Growth, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while RCUS is a turnaround play — different risk/reward profiles.
RCUS carries more volatility with a beta of 0.84 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 20/100). RCUS offers better value entry with a 87.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Arcus Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?